HIV-1 DNA proviral load in treated and untreated HIV-1 seropositive patients

Clinical Microbiology and Infection

Volumn 16, Issue 6, 2010, Pages 640-646

  Re, M C ^b   Vitone, F ^a   Biagetti, C ^c   Schiavone, P ^a   Alessandrini, F ^a   Bon, I ^a   de Crignis, E ^a   Gibellini, D ^a  

^a Microbiology Section   (Italy)

^b NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; POL PROTEIN; TENOFOVIR; ZIDOVUDINE;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LONG TERMINAL REPEAT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS LOAD; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77953941128     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2009.02826.x     Document Type: Article

References (53)

1. Haggerty C, Pitt E, Siliciano R. The latent reservoir for HIV in resting cells and other viral reservoirs during chronic infection: insight from treatment and treatment-interruption trials. Curr Opin HIV AIDS 2006, 1:62-68.
2. Gibellini D, Borderi M, De Crignis E. HIV-1 DNA load analysis in peripheral blood lymphocytes and monocytes from naïve and HAART-treated individuals. J Infect 2008, 56:219-225.
3. Chun TW, Engel D, Mizell SB, Ehler LA, Fauci AS. Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med 1998, 188:83-91.
4. Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 2002, 53:557-593.
5. Pierson T, McArthur J, Siliciano RF. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Ann Rev Immunol 2000, 18:665-708.
6. Pomerantz RJ. Reservoirs, sanctuaries, and residual disease: the hiding spots of HIV-1. HIV Clin Trials 2003, 4:137-143.
7. Siliciano JD, Kajdas J, Finzi D. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003, 9:727-728.
8. Ramratnam B, Ribeiro R, He T. Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquir Immune Defic Syndr 2004, 35:33-37.
9. Larsen K, Han Y, Zhou Y, Siliciano J, Siliciano RF. The multifactorial nature of HIV-1 latency. Trends Mol Med 2004, 10:525-531.
10. Han Y, Lassen K, Monie D. Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J Virol 2004, 78:6122-6133.
11. Lewinski MK, Bisgrove D, Shinn P. Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription. J Virol 2005, 79:6610-6619.
12. Nickle DC, Jensen MA, Shriner D. Evolutionary indicators of human immunodeficiency virus type 1 reservoirs and compartments. J Virol 2003, 77:5540-5546.
13. Tierney C, Lathey JL, Christopherson C. Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy. J Infect Dis 2003, 187:144-148.
14. Riva E, Antonelli G, Scagnolari C. HIV DNA load and level of immunosuppression in treatment-naïve HIV-1 infected patients. J Infect Dis 2003, 187:1826-1828.
15. Yerly S, Günthard HF, Fagard C. Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions. AIDS 2004, 18:1951-1953.
16. Gibellini D, Vitone F, Schiavone P, Ponti C, La M, Re MC. Quantitative detection of human immunodeficiency virus type 1 (HIV-1) proviral DNA in peripheral blood mononuclear cells by SYBR green real-time PCR technique. J Clin Virol 2004, 29:282-289.
17. Kabamba-Mukadi B, Henrivaux P, Ruelle J, Delferrière N, Bodéus M, Goubau P. Human immunodeficiency virus type 1 (HIV-1) proviral DNA load in purified CD4+ cells by LightCycler real-time PCRBMC. Infect Dis 2005, 5:15-20.
18. Hatzakis AE, Touloumi G, Pantazis N. Cellular HIV-1 DNA load predicts HIV-RNA rebound and the outcome of highly active antiretroviral therapy. AIDS 2004, 18:2261-2267.
19. Re MC, Vitone F, Sighinolfi L, Schiavone P, Ghinelli F, Gibellini D. Different patterns of HIV-1 DNA after therapy discontinuation. BMC Infect Dis 2005, 5:69-73.
20. McDermott JL, Giri AA, Martini I. Level of human immunodeficiency virus DNA in peripheral blood mononuclear cells correlates with efficacy of antiretroviral therapy. J Clin Microbiol 1999, 37:2361-2365.
21. Palmisano L, Giuliano M, Chiarotti F. Modifications of HIV-1 DNA and provirus-infected cells during 24 months of intermittent highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2008, 48:68-71.
22. Nicastri E, Palmisano L, Sarmati L. HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (<400 HIV-RNA cp/mL) during different antiretroviral regimens. Curr HIV Res 2008, 6:261-266.
23. Butler SL, Johnson EP, Bushman FD. Human immunodeficiency virus cDNA metabolism: notable stability of two-long terminal repeat circles. J Virol 2002, 76:3739-3747.
24. Pierson TC, Kieffer TL, Ruff CT, Buck C, Gange SJ, Siliciano RF. Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J Virol 2002, 76:4138-4144.
25. Cara A, Vargas J, Keller M. Circular viral DNA and anomalous junction sequence in PBMC of HIV-infected individuals with no detectable plasma HIV RNA. Virol 2002, 292:1-5.
26. Sharkey M, Triques K, Kuritzkes DR, Stevenson M. In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J Virol 2005, 79:5203-5210.
27. Sharkey ME, Teo I, Greenough T. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med 2000, 6:76-81.
28. Brussel A, Mathez D, Broche-Pierre S. Longitudinal monitoring of 2-long terminal repeat circles in peripheral blood mononuclear cells from patients with chronic HIV-1 infection. AIDS 2003, 28:645-652.
29. McDermott JL, Martini I, Ferrari D. Decay of human immunodeficiency virus type 1 unintegrated DNA containing two long terminal repeats in infected individuals after 3 to 8 years of sustained control of viremia. J Clin Microbiol 2005, 43:5272-5274.
30. Kostrikis LG, Touloumi G, Karanicolas R. Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load. J Virol 2002, 76:10099-10108.
31. Zazzi M, Romano L, Catucci M. Evaluation of the presence of 2-LTR HIV-1 unintegrated DNA as a simple molecular predictor of disease progression. J Med Virol 1997, 52:20-25.
32. Re MC, Schiavone P, Vitone F. Low avidity antibody: a reliable method to diagnose a recent HIV-1 infection. New Microbiol 2008, 31:19-26.
33. Suligoi B, Massi M, Galli C. Identifying recent HIV infections using the avidity index and an automated enzyme immunoassay. J Acquir Immune Defic Syndr 2003, 32:424-428.
34. Puchhammer-Stockl E, Schmied B, Rieger A. Low proportion of recent human immunodeficiency virus (HIV) infections among newly diagnosed cases of HIV infection as shown by the presence of HIV-specific antibodies of low avidity. J Clin Microbiol 2005, 43:497-498.
35. Bon I, Gibellini D, Borderi M. Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patients. J Clin Virol 2007, 38:313-320. Epub 2007 Feb 15
36. Felsenstein J. Phylogeny interference package, version 3.5 1993, Seattle, Department of Genetics, University of Washington
37. Garbuglia AR, Calcaterra S, D'Offizi G. HIV-1 DNA burden dynamics in CD4 T cells and monocytes in patients undergoing a transient therapy interruption. J Med Virol 2004, 74:373-381.
38. Re MC, Vitone F, Bon I, Schiavone P, Gibellini D. Meaning of DNA detection during the follow-up of HIV-1 infected patients: a brief review. New Microbiol 2006, 29:81-88.
39. Ramratnam B, Mittler JE, Zhang L. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med 2000, 6:82-85.
40. Sarmati L, Parisi SG, Nicastri E. Association between cellular human immunodeficiency virus DNA level and immunological parameters in patients with undetectable plasma viremia level during highly active antiretroviral therapy. J Clin Microbiol 2005, 43:6183-6185.
41. Ngo-Giang-Huong N, Deveau C, Da Silva I. Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy. AIDS 2001, 15:665-673.
42. Vitone F, Gibellini D, Schiavone P, Re MC. Quantitative DNA proviral detection in HIV-1 patients treated with antiretroviral therapy. J Clin Virol 2005, 33:195-200.
43. Carr JM, Cheney KM, Coolen C. Development of methods for coordinate measurement of total cell-associated and integrated human immunodeficiency virus type 1 (HIV-1) DNA forms in routine clinical samples: levels are not associated with clinical parameters, but low levels of integrated HIV-1 DNA may be prognostic for continued successful therapy. J Clin Microbiol 2007, 45:1288-1297.
44. Morlese J, Teo IA, Choi JW, Gazzard B, Shaunak S. Identification of two mutually exclusive groups after long-term monitoring of HIV DNA 2-LTR circle copy number in patients on HAART. AIDS 2003, 17:679-683.
45. Panther LA, Coombs RW, Aung SA, dela Rosa C, Gretch D, Corey L. Unintegrated HIV-1 circular 2-LTR proviral DNA as a marker of recently infected cells: relative effect of recombinant CD4, zidovudine, and saquinavir in vitro. J Med Virol 1999, 58:165-173.
46. Ibáñez A, Puig T, Elias J, Clotet B, Ruiz Martínez MA. Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients. AIDS 1999, 13:1045-1049.
47. De Rossi A, Walker AS, De Forni D, Gibb DM. Paediatric European Network for treatment of AIDS (PENTA). Biphasic decay of cell-associated HIV-1 DNA in HIV-1-infected children on antiretroviral therapy. AIDS 2002, 16:1961-1963.
48. Finzi D, Blankson J, Siliciano JD. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999, 5:512-517.
49. Strain MC, Gunthard HF, Havlir DV. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci USA 2003, 100:4819-4824.
50. Finzi D, Hermankova M, Pierson T. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295-1300.
51. Pellegrin I, Caumont A, Garrigue I. Predictive value of provirus load and DNA human immunodeficiency virus genotype for successful abacavir-based simplified therapy. J Infect Dis 2003, 187:38-46.
52. Kay MS. Silent, but deadly - eliminating reservoirs of latent HIV. Trends Biotechnol 2003, 21:420-423.
53. Nickle DC, Shriner D, Mittler JE, Frenkel LM, Mullins JI. Importance and detection of virus reservoirs and compartments of HIV infection. Curr Opin Microbiol 2003, 6:410-416.